Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Article
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
adjusted hazard ratio
Adults
age
association
B.1.1.529
B.1.617.2
benefit
conditions
coronavirus
covariate
death
Effectiveness
Efficacy
eligibility criteria
eligible
Hospitalization
Nirmatrelvir
no evidence of
Older
omicron
outcome
Patient
Protease inhibitor
receive
Regression model
SARS-CoV-2
SARS-CoV-2 immunity
service
severe coronavirus disease
shown
significantly lower
sociodemographic factors
study period
therapy
treated patient
Treatment
untreated patient
variant
was used
were assessed
[DOI] 10.1056/NEJMoa2204919 PMC 바로가기 [Article Type] Article
[DOI] 10.1056/NEJMoa2204919 PMC 바로가기 [Article Type] Article